Cannabis is commonly used among people who drink alcohol, but findings are mixed regarding the direction of this relationship. The type of cannabis used [high-cannabidiol (CBD) vs. high-delta-9tetrahydrocannabinol (THC)] and motives for use (i.e., whether cannabis is used to treat a medical condition) may influence the relationship between cannabis and drinking. Specifically, CBD has shown preclinical promise in reducing alcohol consumption, and medical cannabis users report using cannabis to reduce drinking. This study leverages survey data from cannabis users who drink alcohol ( = 533). Respondents were categorized as using cannabis to treat (CTT) a medical condition or as individuals whose cannabis use is not intended to treat (NCTT) a medical condition and grouped based on the THC/CBD ratio of the flower or edible cannabis they typically use (e.g., "High-THC/CBD," "Medium-THC/CBD" and "Low-THC/CBD"). The CTT group ( = 412) reported drinking significantly less frequently than the NCTT group ( = 121). Cannabinoid content of flower cannabis was associated with alcohol consumed on cannabis-use days, such that individuals in the High-THC/CBD group drink more on cannabis-use days compared to the Medium-THC/CBD group. Cannabinoid content of edible cannabis was associated with drinks per drinking occasion, such that the High-THC/CBD group consumed the most drinks and the Low-THC/CBD group consumed the fewest. For both edible and flower groupings, higher-THC/CBD cannabis was associated with more frequent co-use than lower-THC/CBD cannabis. Results suggest that whether someone uses cannabis to treat a medical condition may impact their drinking frequency, and the cannabinoid content in flower and edible cannabis impacts alcohol consumption.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779394 | PMC |
http://dx.doi.org/10.3389/fpsyt.2020.613243 | DOI Listing |
Prim Care Companion CNS Disord
January 2025
Department of Psychiatry, Iqraa International Hospital and Research Centre, Calicut, Kerala, India.
Chem Biodivers
January 2025
CSIR-CIMAP: Central Institute of Medicinal and Aromatic Plants CSIR, Botany and Pharmacognosy, Kukrail Picnic Spot Road, 226015, Lucknow, INDIA.
Cannabis sativa L. is an important medicinal plant with high commercial value. In recent years, the research interest in cannabidiol (CBD) and terpene-rich cannabis has been rapidly expanding due to their high therapeutic potential.
View Article and Find Full Text PDFClin Pract
January 2025
Fondazione Paolo Procacci, 00193 Roma, Italy.
Chronic non-cancer pain, defined by the Center for Disease Control and Prevention (CDC) as lasting beyond three months, significantly affects individuals' quality of life and is often linked to various medical conditions or injuries. Its management is complex. Cannabis, containing the key compounds Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has garnered interest for its potential in pain management, though it remains controversial due to its psychoactive effects and illegal status in many countries.
View Article and Find Full Text PDFSubst Use Misuse
January 2025
Advancing New Standards in Reproductive Health, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, Oakland, California, USA.
Objective: To explore recently/currently pregnant people's experiences and views about cannabis use during pregnancy and their associated support for policies that punish pregnant people who use cannabis.
Methods: A market research firm administered a survey (May-June 2022) to pregnant and recently pregnant people ages 18-49 regarding their attitudes about cannabis use policies and practices. We used multivariable regression to assess whether cannabis use and beliefs are associated with support for punishing people who use cannabis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!